Companies Dominating the Rapid Antigen Testing Landscape
- iHealth Labs, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- NeoDx Biotech Labs
- Abbott Laboratories
- Affinity Biologics, Inc.
- Siemens Healthineers AG
- Epitope Diagnostics, Inc.
- Sino Biological, Inc.
- R-Biopharma AG
- Cell Biolabs, Inc.
- Thermo Fisher Scientific
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of rapid antigen testing is assessed at USD 27.2 billion.
The rapid antigen testing market size was over USD 25.68 billion in 2024 and is projected to reach USD 64.96 billion by 2037, growing at around 7.4% CAGR during the forecast period i.e., between 2025-2037. The growing adoption of rapid antigen tests for diagnosis of other viral infections, the growing shift towards digitalization in the healthcare industry, and growing incidences of infectious diseases will boost the market growth.
North America industry is anticipated to hold largest revenue share of 37% by 2037, due to increasing prevalence of antibiotic-resistant infections and respiratory illnesses in the region.
The major players in the market are iHealth Labs, Inc., NeoDx Biotech Labs, Abbott Laboratories, Affinity Biologics, Inc., Siemens Healthineers AG, Epitope Diagnostics, Inc., Sino Biological, Inc., R-Biopharma AG, Cell Biolabs, Inc, Thermo Fisher Scientific, Kaneka Corporation, FUJIFILM Corporation, Otsuka Pharmaceutical Co., Ltd., Hitachi, Ltd., Shionogi & Co., Ltd. and others.
